Jesus San-Miguel
Overview
Explore the profile of Jesus San-Miguel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
6594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rosinol L, Hebraud B, Oriol A, Colin A, Rios Tamayo R, Hulin C, et al.
Front Oncol
. 2023 Nov;
13:1197340.
PMID: 38023148
Objective: Providing the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone...
12.
Paiva B, Zherniakova A, Nunez-Cordoba J, Rodriguez-Otero P, Shi Q, Munshi N, et al.
Blood Adv
. 2023 Aug;
8(1):219-223.
PMID: 37639322
No abstract available.
13.
Dimopoulos M, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison S, et al.
Lancet Oncol
. 2023 Jul;
24(7):e293-e311.
PMID: 37414019
Here, the International Myeloma Working Group (IMWG) updates its clinical practice recommendations for the management of multiple myeloma-related renal impairment on the basis of data published until Dec 31, 2022....
14.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M, et al.
N Engl J Med
. 2023 Jun;
389(4):335-347.
PMID: 37272512
Background: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment...
15.
Ludwig H, Terpos E, van de Donk N, Mateos M, Moreau P, Dimopoulos M, et al.
Lancet Oncol
. 2023 Jun;
24(6):e255-e269.
PMID: 37269857
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine release syndrome, immune effector cell-associated...
16.
Treon S, Tedeschi A, San-Miguel J, Garcia-Sanz R, Anderson K, Kimby E, et al.
Semin Hematol
. 2023 May;
60(2):97-106.
PMID: 37173155
Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for diagnosis and response assessment. Since the initial consensus reports...
17.
Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, et al.
Leukemia
. 2023 May;
37(6):1175-1185.
PMID: 37142661
In the post-pandemic COVID-19 period, human activities have returned to normal and COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an increased risk for breakthrough infections...
18.
Merlini G, Sarosiek S, Benevolo G, Cao X, Dimopoulos M, Garcia-Sanz R, et al.
Semin Hematol
. 2023 Apr;
60(2):113-117.
PMID: 37099030
Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis...
19.
Buske C, Castillo J, Abeykoon J, Advani R, Arulogun S, Branagan A, et al.
Semin Hematol
. 2023 Apr;
60(2):73-79.
PMID: 37099027
Consensus Panel 1 (CP1) of the 11 International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naïve patients with WM. The panel reiterated...
20.
Weisel K, Dimopoulos M, San-Miguel J, Paner A, Engelhardt M, Taylor F, et al.
Hemasphere
. 2023 Mar;
7(3):e843.
PMID: 36860268
Triplet regimens containing immunomodulatory drugs and proteasome inhibitors (PIs) have improved outcomes and extended survival for patients with relapsed/refractory multiple myeloma (RRMM). We evaluated updated health-related quality of life (HRQoL)...